China Biotech Out-Licensing Talent: Pay and Gap | SunTzu China

One. The deals are rising, and what gets valued is changing. China recorded 116 out-licensing transactions in the first half of 2026, up 28.9% year on year, with USD 4.97bn of upfront payments, up 68.4%, and USD 99.89bn of total potential value, up 42.0%. More telling is the shift in what is being bought: more than half of the drugs China out-licensed in 2025 were at pre-clinical or Phase I stage at signing, and the largest October deals pushed the target to the platform level.

Two. The missing people are not in the laboratory. China accounts for 33.7% of innovative drugs in development worldwide, first for several years running, yet only 410 multi-regional clinical trials ran in 2025, or 13.7% of the national clinical trial total. That gap corresponds to three job families: international regulatory filing, multi-regional clinical operations and transaction negotiation.

Three. Inside one company, the same role overseas pays about 2.6 times the domestic rate. A leading developer disclosed in its 2025 annual report average R&D staff pay of RMB 1.021m, split between RMB 627,000 for domestic staff and RMB 1.611m overseas. The same role and degree, priced 2.6 times apart because of the regulatory system worked in: a wider spread than between any two adjacent degree tiers, and the clearest price signal in cross-border hiring.

Four. City position is set by industrial parks, not university density. Across first-half biotech postings, new tier-one cities took 32.8%, tier-two 23.5% and first-tier cities 19.8%, with the three major clusters accounting for 45.6%. Suzhou, home to more than 4,200 biotech companies and RMB 250bn of above-scale output, produced about 30% of China's newly listed pharmaceutical companies. Where a graduate ends up is now decided by employers in the park, not the university ranking.

1. From a China pharma talent gap argument to a structural reading

Start with the demand floor. On the regulator's basis, China's out-licensing value reached about USD 110bn in the first half of 2026, four-fifths of the USD 135.655bn recorded for all of 2025, the year this total first overtook the United States and reached 49% of global deal value. The contract basis gives different figures for the same period: 116 transactions, USD 4.97bn of upfront payments and USD 99.89bn of total potential value, up 28.9%, 68.4% and 42.0%. The two bases count different things, so this report uses the deal-count basis as its main series and the total-value basis as a reference, without mixing them in one calculation.

The stage of the assets being bought matters more than the money. More than half of the drugs China out-licensed in 2025 were at pre-clinical or Phase I stage at signing, and the large October transactions extended that trend to the platform level. One messenger-RNA platform licence closed at USD 575m upfront against roughly USD 7.8bn of potential value, the asset still in early clinical development and the buyer paying chiefly for the delivery technology; in the same week, another deal sold a pipeline on its own while the seller kept the platform. As the target shifts from validated assets toward early molecules and platforms, the point at which value is priced moves earlier.

Annual reports give the industry's two clearest hiring paths. One developer led by the domestic market reported 20,602 employees for 2025, up 1.8%, of whom 5,684, or 27.59%, were R&D staff, with revenue per head of RMB 1.5353m and pay per head of RMB 343,100. About 95% of its revenue came from China, and the balance of its headcount sat in production, quality control, sales and market access, needing a large commercial force for hospital channels and reimbursement negotiations.

The other developer, growing on overseas markets, reported 11,825 employees, of whom 4,281, or 36.20%, were R&D staff, with revenue per head of RMB 3.2326m and pay per head of RMB 977,300. Its overseas revenue rose 53% and approached 70% of the total, with Phase III programmes designed from the outset for the United States, Europe and Asia. Pay per head differs roughly three times between the two, revenue per head about double, and R&D staff share by nearly nine points.

The comparison shows that the definition of hiring inside one industry has split. The first type needs executors for scaled commercialisation and production quality; the second needs professionals in global clinical development, regulatory affairs and medical affairs. Demand for the two does not rise and fall together, so a single "pharma talent" total overstates one side and understates the other.

A second set points the other way. Average headcount in pharmaceutical manufacturing fell 3% in 2025, while the number of enterprises rose 4.92% to 9,875 and loss-making firms numbered 2,838, or 28.74%. More companies and less total employment indicate that new entrants are small and incumbents are trimming.

Sub-sector divergence is equally clear: biologics revenue rose 7.5% and total profit 37.9%; pharmaceutical equipment revenue fell 4.9% while profit rose 27.4%; chemical formulations were broadly flat; traditional Chinese medicine fell on both lines. Behind the headline of falling average employment, contraction and expansion are happening at once. The segments hit hardest are traditional generics exposed to procurement and price governance, while roles in biologics and innovative drugs keep growing. The demand increment sits in regulatory, clinical and business development roles and does not move in step with generics.

2. Job-family benchmarks: bands, midpoints and ceilings

The table below groups roles along the out-licensing chain by job family and gives the starting band and midpoint. One caveat comes first. The bands come from two sources: recruitment-platform postings, which include headhunter-listed roles and are mostly anonymised employer budget ranges rather than final offer terms; and listed-company annual reports, which are all-in per-head figures including equity and social insurance cost. The bases cannot be subtracted, so the table compares within a layer only, and each midpoint is the arithmetic midpoint of the band, not a percentile statistic.

Finding one: the spread between job families exceeds the spread between employers. In the same table, the top of the business development and overseas commercial bands reaches RMB 1.8m to 2.0m a year, while clinical operations and regulatory entry roles start at RMB 100k to 150k. The job family a candidate applies to affects pay more than the company, and this is the most direct price projection of where the difficulty sits: the roles that command a premium and the roles that are hard to fill are the same.

Finding two: international filing experience is the fastest-moving price step. Among open postings, associate director roles in regulatory affairs labelled "international filing" are budgeted above the domestic-filing role at the same grade, and candidates with a complete filing record often command above the posted ceiling. The gate is the regulatory system rather than the degree: five years in domestic registration and one filing through an overseas regulator sit in different price lists.

Finding three: role-level and per-head figures cannot be mixed. The final row of Table 1 is an all-in per-head figure for R&D staff; the other rows are role-level budget bands. Subtracting one from the other produces the nonsensical reading that one industry pays RMB 100,000 and RMB 1m at once. The usable method is to split by camp: an annual report tells you what a company spends on people overall, a posting budget tells you what it pays for one position, and one number cannot answer both.

3. Splitting by degree tier: three price curves inside one industry

The previous section split the market by job family; this one splits it by degree tier. In life sciences, graduates from the same cohort face entirely different role lists depending on their degree, and on the cross-border side a further experience is priced beyond the degree: whether the candidate has completed a filing or a clinical programme under an overseas framework. The table below merges the posting and annual report bases by degree tier.

Observation one: the steps between degree tiers are multiples, and the overseas gap is larger still. Bachelor to master is roughly double and master to doctorate about double, while the same degree split between a domestic and an overseas base is about 2.6 times, wider than the gap between any two adjacent tiers. The first variable in pricing on the cross-border side is therefore the regulatory system worked in, and the degree second: for graduates entering the field, which regulator they work under shapes their pay five years out more than which degree they take.

Observation two: the bachelor gate opens onto execution roles while the master is the gate to professional roles. Among open postings, regulatory and clinical roles list bachelor as the entry degree in most cases, but roles labelled "independently leads a filing" or "independently leads a trial" generally require master and above. Bachelor candidates can enter the chain, but only at execution and support positions; moving up takes two additions, a complete project record and hands-on work under an overseas framework.

Observation three: there is a gap between the posted band and actual outlay. Innovative drug pay structures normally include an annual bonus, milestone participation and options, with employer social insurance and housing fund contributions on top. On roles budgeted below RMB 30,000 a month, the distance between posted pay and take-home can exceed 20%; on business development roles carrying options or milestone sharing, variable pay can exceed the fixed portion. Treating posted bands as a comparable basis across companies overstates the appeal of lower tiers and understates what milestone-heavy roles return.

4. Clustering and price: how location reprices the same CV

The third dimension is geography. Life sciences is among the most vertically specialised industries, and the same CV reaches more roles at a higher price depending on whether the candidate sits inside a cluster. The table sets cluster metrics against pay anchors for five regions, listing an anchor only where a comparable posting exists.

Finding one: for first-tier cities the reading is job density, for new tier-one cities it is job growth. Across first-half biotech postings, new tier-one cities took 32.8%, tier-two cities 23.5% and first-tier cities 19.8%. The advantage of first-tier cities is the density of head offices and lead employers; that of new tier-one cities is the increment, since expanding companies site new roles where cost is lower, park infrastructure newer and approvals faster. The question for a candidate is whether they want a head-office role or a growth role.

Finding two: the number of employers in a park decides role supply more than university density does. Suzhou, with more than 4,200 biotech companies and RMB 250bn of above-scale output, produces about 30% of China's newly listed pharmaceutical companies, and one park alone signed 9 out-licensing deals with USD 2.115bn of upfront payments in the first half. The cause is that up and downstream links can be matched within one geography; the density of employers decides the resources a single role can draw on, and the choice set available to a candidate.

Finding three: the overseas-versus-domestic pay gap is the most direct talent signal of this round. Inside one company, overseas R&D staff are paid about 2.6 times the domestic average. Part of that gap is local living cost, part is the scarcity of regulatory experience. For an employer this implies two routes: staff overseas roles locally, or develop internationally qualified people in China and convert part of the gap into long-term incentives. For a candidate it means international filing and multi-regional clinical experience built in any Chinese city is a separately priced capability.

5. Five trends already visible in the data

Stack the four readings together and five directional judgements follow. Each is a change already observable in public data.

More than half of the drugs China out-licensed in 2025 were at pre-clinical or Phase I stage at signing, and the large transactions this year pushed the target up to the platform level, where the buyer purchases a technical base capable of producing molecules one after another and the value of any single molecule recedes. Pricing therefore moves earlier: people who can judge an asset before it reads out are scarcer than those who compute commercial value after Phase III.

Upfront payments reached USD 4.97bn in the first half, up 68.4%, faster than the 42.0% growth in total potential value, and the year-to-date total has passed USD 10bn. Upfront cash is the only part of a deal that lands at signing, so a rising share raises the certainty of cash flow while raising the complexity of the structure, in which molecule rights, regional rights, indication carve-outs and stage payments are recombined. Someone has to price each structure at the table, and that capability commands the industry's strongest bargaining position.

A clear gap separates pipeline volume from international execution capability: China accounts for 33.7% of innovative drugs in development worldwide, while multi-regional trials are 13.7% of the national clinical trial total. On a five-year licensing cycle, deals signed today need overseas filings and multi-regional trials completed over the next three to five years, translating into sustained demand for regulatory affairs and clinical operations roles whose rhythm is set by contracts already signed, not by the deal count day to day.

Average pharmaceutical manufacturing headcount fell 3%, the enterprise count rose 4.92% and loss-making firms reached 28.74%, all at once. The segments hit hardest are traditional generics exposed to procurement and price governance, while roles in biologics and innovative drugs keep growing. The headline that "pharma is shedding jobs" therefore does not hold inside the industry: at the same time, one part is trimming headcount while another competes hard for people.

Among postings, degree requirements have changed little in recent years, but roles described as "international filing", "multi-regional trial" or "FDA submission" are increasing and generally carry a higher budget band. The roughly 2.6-times overseas-versus-domestic gap in one company's annual report puts a number on the trend. In that structure, grading by degree or years of service reflects real pricing less and less, and whether a candidate has carried a process through an overseas regulator is the earlier signal.

6. Limits, uncertainty and indicators worth tracking

All four readings carry explicit boundaries, and three of them can be revised on definitional grounds.

Four indicators worth tracking: first, the stage distribution of out-licensing targets by quarter, which sets demand for regulatory and clinical roles three to five years out; second, the share of postings tagged "international filing" or "multi-regional trial", the most direct reading of where the gap points; third, the overseas-versus-domestic R&D pay gap in leading companies' annual reports, which moves earlier than any average; fourth, the number of newly established companies inside industry parks, which sets the geography of supply over the next three years. None requires commissioned research; recording the next round of public data on the same basis is enough.

7. What this means for employers hiring in China

This section does not discuss individual companies' recruiting tactics. It sets out what the readings mean for employers and for candidates.

The hiring difficulty on the cross-border chain now sits in the accuracy of the role profile. Among open postings, regulatory and clinical budgets span a very wide range, and the same "registration director" title may be budgeted at RMB 400,000 at one company and RMB 1.2m at another, the difference turning on whether the role must complete an overseas filing independently. Rewriting a job description from a grade title into concrete process responsibility, whether the candidate has filed independently or led a multi-regional trial, is the most direct way to widen the pool and land the budget in the right band.

Second, pay benchmarking has to be done in layers. Benchmarking a domestic registration role against an international one produces the conclusion that no one can be hired; splitting job family, regulatory experience and city into three benchmarks produces bands you can act on. Third, the 2.6-times overseas-versus-domestic gap points to a substitute route: developing internationally qualified people in China and converting part of the gap into long-term incentives usually costs less than a permanent overseas assignment.

For an international employer, position in this market depends on the differentiators that sit outside pay structure. Chinese companies' out-licensing deals are increasing, and demand for international regulatory, multi-regional clinical and overseas commercial people is rising, but people fluent in an overseas regulatory system who can also push processes inside a Chinese team remain limited. The advantage of a foreign employer is that this experience is already internal; the question is how to turn it into visible value for candidates.

Two routes are workable. First, concentrate roles where regulatory-system experience is transferable, such as international registration and multi-regional clinical operations, since working inside an overseas framework is itself a career goal for these candidates. Second, put the differentiators ahead of pay, including the completeness of the regulatory system, cross-market project exposure and a steadier working rhythm. One point needs care: in Chinese companies' budget lists, foreign-national and local candidates in regulatory and clinical roles are often priced on separate tracks, so a single band should not be stretched across both.

Three structural features of this market also catch foreign employers out, and all three can be planned around. The first is that the counterparty has changed. Chinese biotechs now hold non-dilutive cash from licensing deals, and once a company has USD 500m or more of upfront payments on the balance sheet it can pay international rates for the same regulatory and clinical people a foreign employer is trying to hire, removing the traditional pay advantage of a multinational. The second is framework fluency as a screening reality: what a Chinese candidate can demonstrate is filings lodged with CDE and trials run to local practice, so an employer hiring against FDA or EMA requirements is testing for a capability that may not yet exist and should budget for training and a first supervised filing. The third is that the same people are approached from both directions, by Chinese firms expanding overseas and by foreign firms coming in, so a foreign employer competes not only with other multinationals but with the newly capitalised Chinese biotech next door. Building the offer around framework access and project scope before the hiring window opens is worth more than adjusting pay after the shortlist has thinned.

8. Data notes

Nature of data: deal data, workforce data and pay bands come from regulator and industry association disclosures, listed-company annual and interim reports, and recruitment-platform research, cross-checked. Anything derived is flagged in the notes beneath the relevant table.

Period: deal and company pay data cover 2025 annual reports and 2026 H1; postings reflect 2026 open roles; city industry output covers 2025 and 2026 H1; park deal values cover 2026 H1.

Pay basis: recruitment-platform figures are employer budget ranges including headhunter-listed roles and are not binding offer terms; annual report figures are all-in pay per head including equity and social insurance cost and are above cash income. The bases cannot be subtracted directly; this report compares within a layer only.

Role classification: business development covers deal negotiation, due diligence and alliance management; regulatory affairs covers drug registration and filing, including international filing; clinical development covers clinical operations, project management and monitoring; medical affairs covers medical monitoring and medical science; pharmacovigilance and biostatistics covers safety monitoring and statistics; overseas commercialisation covers market access, sales management and channels.

Degree mapping: bachelor, master and doctorate are degree tiers and do not correspond to internal job grades; the same degree maps to noticeably different role lists at different employers, so bands are given on a merged basis.

City data: cluster metrics follow government releases, recruitment-platform research and authoritative media on periods that are not fully aligned; Guangzhou and Chengdu have no same-basis posting disclosing pay by city, so the corresponding cells are left blank.

Disclaimer: the pay bands here are merged from public information. Actual outcomes vary materially with company size, role direction, regulatory experience and negotiation, and nothing here constitutes pay or investment advice.

Deal and clinical data. 2026 first-half out-licensing totals of 116 transactions, USD 4.97bn of upfront payments and USD 99.89bn of total potential value, with year-on-year growth rates (industry data platform, cited in a CXO company's 2026 interim report); 1,313 Phase I to III clinical trial disclosures and 1,908 IND approvals in 2026 H1 (same interim report); first-half 2026 out-licensing value of about USD 110bn and full-year 2025 value of USD 135.655bn (regulator disclosures); 410 multi-regional clinical trials in 2025, or 13.7% of the annual total, and a 33.7% global share of innovative drugs in development (industry association disclosures).

Workforce data. Total employees, R&D headcount and share, revenue per head, pay per head, domestic and overseas R&D pay, and the revenue split (2025 annual reports of two leading developers); 2025 pharmaceutical manufacturing average headcount down 3%, 9,875 enterprises, 2,838 loss-making firms and sub-sector revenue and profit figures (industry association's 2025 pharmaceutical industry economic performance report).

Pay and role basis. Budget bands for drug registration director, clinical registration director and API international registration director roles (published recruitment postings, 2026); bands for business development, clinical development, medical affairs, pharmacovigilance and biostatistics, and overseas commercialisation (published postings merged with annual-report basis).

City and regional data. First-half 2026 biotech posting shares by city tier and city cluster, and key-role posting shares for Beijing and Shanghai (recruitment-platform research reports); Suzhou biotech company count, above-scale output and park out-licensing deals (Economic Information Daily and related local industry disclosures); Shanghai, Beijing and Guangzhou biotech company counts (recruitment-platform research reports).

Indicator definitions and source tiering. The band midpoint is the arithmetic midpoint of a band's bounds, calculated by this report; posting bands are recruitment-platform employer budget ranges; per-head pay is all-in including equity and social insurance cost. Only four source categories are used: government and regulator disclosures, industry association disclosures, listed-company annual and interim reports, and recruitment-platform research. The report does not use percentile tables back-calculated by aggregator sites, data from training or lead-generation sites, city pay guides from competing recruitment firms, or pay compilations without a named source.

The hard part of cross-border hiring in Chinese life sciences is rarely the number of roles. It is the fit between a role and a regulatory record: the same registration title, whether the candidate has lodged an overseas filing; the same clinical title, whether the candidate has designed and run a multi-regional trial. Any one mismatch narrows a pool to single digits. As a life sciences recruiter China operation tracking cross-border drug development, SunTzu China covers biotech recruitment China mandates across business development, regulatory affairs, clinical development and overseas commercialisation, with pay benchmarking, supply mapping and targeted search for foreign and local employers hiring in China.

If you are building an international regulatory or clinical team, or benchmarking drug registration talent and biotech business development jobs in China, get in touch for a supply and pricing assessment built on your role list. We also support pharmaceutical recruiter China mandates and clinical development hiring China programmes, including offer design for foreign-national and local candidate tracks, and can share regional pay anchors and a supply map covering pharmaceutical salary China data.